No Data
Zhangzhou Pientzehuang Pharmaceutical is advancing the National Medicine Hall plan with over 30 new establishments in the first quarter | Direct hit at the Earnings Conference.
① In the first quarter of 2025, Zhangzhou Pientzehuang Pharmaceutical will open over 30 new Zhangzhou Pientzehuang Medical Halls, with plans to establish approximately 600 more across the country in the future. ② The focus will be on opening Zhangzhou Pientzehuang Medical Halls in blank areas outside Fujian and Guangdong provinces, and increasing efforts to penetrate the market in prefecture-level cities and county-level regions.
BEIGENE's Q1 loss narrowed to 94.503 million yuan, with Baiyueze and Baizean sales revenue increasing.
In the first quarter of 2025, BEIGENE achieved revenue of 8.048 billion yuan, a year-on-year increase of 50.2%; the net income attributable to the parent was a loss of 94.503 million yuan, compared to a loss of 1.908 billion yuan in the same period last year; In recent years, with policy support, China's Innovative Drugs Industry has entered a period of rapid development. In 2024, the industry will usher in a new round of policy dividends, and the research and development results of domestic Innovative Drugs will experience explosive growth.
Earnings Preview: BeiGene
China's Consumer Prices Fall for Third Month; PPI Fall the Most in 6 Months
The Concept of Innovative Drugs has been severely attacked! Trump suddenly posts: We need to reduce drug prices in the USA by up to 80% immediately!
① The President of the USA, Trump, will sign an executive order on Monday aimed at reducing the prices of USA prescription pharmaceuticals and medications by 30% to 80% immediately; ② The executive order will implement a "most-favored-nation policy," aligning the prices paid in the USA with those of the country with the lowest drug prices in the world; ③ Trump referred to this executive order as "one of the most important executive orders in USA history," expecting it to save trillions of dollars.
China's Exports Jump 8% in April Despite Tariff Tensions